Nkarta, Inc. (NKTX) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Nkarta, Inc. is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies, primarily targeting autoimmune diseases. The company's lead product candidate is NKX019, a CAR NK-cell therapy targeting the CD19 antigen. The company operates as a single reporting segment and is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(21.7) million | $(28.3) million | $(76.7) million | $(82.9) million |
| Net Loss Per Share | $(0.29) | $(0.39) | $(1.04) | $(1.26) |
| Operating Expenses | $27.3 million | $33.8 million | $91.0 million | $97.3 million |
| Cash & Investments | $316.5 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $620.9 million (as of Sept 30, 2025) | |||
| Operating Cash Flow | N/A | $(67.1) million | $(74.9) million |
Material Changes vs. Prior Period
- Reduced Operating Expenses: Total operating expenses decreased by $6.5 million in Q3 2025 compared to Q3 2024. This reduction was driven primarily by a $3.2 million decrease in personnel costs and a $1.2 million decrease in program costs, largely due to a 34% workforce reduction (53 positions) announced in March 2025.
- Improved Net Loss: Net loss narrowed by $6.6 million in Q3 2025 compared to the prior year quarter, reflecting the cost containment measures.
- Asset Impairment: The company recorded a $0.8 million impairment charge related to right-of-use assets in Q3 2025. This was triggered by a sustained decline in the trading price of common stock, causing market capitalization to fall below net asset value.
- Interest Income Decline: Interest income decreased to $3.9 million in Q3 2025 from $5.5 million in Q3 2024, attributed to lower average investment balances and interest rates.
- Other Income: Other income increased to $1.7 million in Q3 2025, primarily due to the recognition of $1.5 million in Employee Retention Credit (ERC) payments received from the IRS.
Guidance, Outlook, and Risks
- Clinical Progress: The company is advancing NKX019 in Phase 1 trials for autoimmune diseases (Ntrust-1 for lupus nephritis and primary membranous nephropathy; Ntrust-2 for systemic sclerosis, myositis, and AAV). In November 2025, the company reported deep B-cell depletion in patients receiving a modified lymphodepleting conditioning regimen (Fludarabine and Cyclophosphamide) and initiated enrollment in the second dose-escalation cohort.
- Pipeline Deprioritization: Nkarta has deprioritized the development of NKX019 for B-cell malignancies and the NKX101 program for hematologic malignancies to focus resources on autoimmune indications.
- Liquidity Outlook: Management believes current cash, cash equivalents, and investments ($316.5 million) are sufficient to fund operations for at least 12 months from the filing date. The company expects to continue incurring significant losses and will require additional capital to advance clinical development and commercialization.
- Key Risks:
- Capital Requirements: Significant additional funding will be needed; failure to raise capital could force further cost-cutting or program delays.
- Clinical Uncertainty: No cell therapies are currently approved for autoimmune diseases; clinical success is not guaranteed.
- Manufacturing: Reliance on a sole supplier (Miltenyi) for critical manufacturing equipment and reagents poses supply chain risks.
- Intellectual Property: Dependence on licensed technology from National University of Singapore and St. Jude Children's Research Hospital.
Investor Verification Checklist
- Verify the timeline and sufficiency of the $316.5 million cash runway against the projected burn rate for the Ntrust-1 and Ntrust-2 clinical trials.
- Confirm the status of the workforce reduction and whether the $5.4 million severance liability has been fully settled or remains on the balance sheet.
- Review the specific terms of the CRISPR Therapeutics collaboration, noting that CRISPR opted out of the NKX070 program in September 2025, and assess the impact on future milestone payments.
- Monitor the impairment of long-lived assets to determine if further charges are likely if the stock price remains below net asset value.
- Assess the supply chain risk associated with the sole supplier (Miltenyi) for the CliniMACS Plus system and reagents, particularly regarding expiration dates and potential tariff impacts.